Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Zealand Pharma Aktieselskabet    ZEAL   DK0060257814

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
120(c) 119(c) 118(c) 118(c) 117.5(c) Last
59 061 33 569 57 405 77 131 55 084 Volume
0.00% -0.83% -0.84% 0.00% -0.42% Change
More quotes
Financials ( DKK)
Sales 2017 168 M
EBIT 2017 -242 M
Net income 2017 -265 M
Finance 2017 48,5 M
Yield 2017 -
Sales 2018 247 M
EBIT 2018 -240 M
Net income 2018 -246 M
Finance 2018 107 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 21,3x
EV / Sales2018 14,2x
Capitalization 3 613 M
More Financials
Company
Zealand Pharma A/S is a biotechnology company.It focuses on the discovery, design and development of peptide based medicines.The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Glostrup, Denmark. 
More about the company
Surperformance© ratings of Zealand Pharma Aktieselska
Trading Rating : Investor Rating :
More Ratings
Latest news on ZEALAND PHARMA AKTIESELSKA
10/13 ZEALAND PHARMA AKTIESELSKABET : has initiated a clinical trial to evaluate the p..
10/12 ZEALAND PHARMA AKTIESELSKABET : has initiated a clinical trial to evaluate the p..
10/06 ZEALAND PHARMA AKTIESELSKABET : and Torrey Pines Institute for Molecular Studies..
10/04 ZEALAND PHARMA AKTIESELSKABET : and Torrey Pines Institute for Molecular Studies..
09/22 ZEALAND PHARMA AKTIESELSKABET : increases its share capital as a consequence of ..
09/15 SANOFI : Zealand Pharma AS Soliqua 100 33 provided earlier blood sugar control t..
09/13 ZEALAND PHARMA AKTIESELSKABET : Soliqua® 100/33 provided earlier blood sugar con..
09/11 SANOFI : Zealand and Orbit Discovery enter into research collaboration
09/08 ZEALAND PHARMA AKTIESELSKABET : and Orbit Discovery enter into research collabor..
09/07 SANOFI : Zealand Pharma to present at Morgan Stanley Global Healthcare Conferenc..
More news
Sector news : Bio Therapeutic Drugs
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/20Head of MI5 Andrew Parker: "We've seen a dramatic up-shift in threat this yea..
40
10/19Head of MI5 Andrew Parker: "We've seen a dramatic up-shift in threat this yea..
48
10/18MI5 boss Andrew Parker says the UK is facing an 'intense' terrorism threat &a..
29
10/18The U.K. is seeing more plots coming at a faster tempo, says MI5 head Andrew ..
34
10/18Head of MI5 Andrew Parker: Britain is facing 'worst terror threat I've ever s..
3
More tweets
Qtime:78
News from SeekingAlpha
05/23 Zealand advances dasiglucagon for potential use in artificial pancreas system..
01/04 Sanofi's Soliqua 100/33 now available in U.S
2016 European advisory committee backs Sanofi's diabetes med Suliqua
2016 Zealand Pharma reports Q3 results
2016 Zealand Pharma reports 1h16 results
Chart ZEALAND PHARMA AKTIESELSKA
Duration : Period :
Zealand Pharma Aktieselska Technical Analysis Chart | ZEAL | DK0060257814 | 4-Traders
Technical analysis trends ZEALAND PHARMA AKTIESELSKA
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 169  DKK
Spread / Average Target 44%
EPS Revisions
Managers
NameTitle
Britt Meelby Jensen President & Chief Executive Officer
Alf Gunnar Martin Nicklasson Chairman
Mats Blom Chief Financial Officer & Senior Vice President
Adam Steensberg Chief Medical Officer & Senior Vice President
Parker Andrew Chief Science Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ZEALAND PHARMA AKTIESELSKABET11.74%572
GILEAD SCIENCES11.73%106 054
REGENERON PHARMACEUTICALS19.69%46 395
VERTEX PHARMACEUTICALS110.07%38 985
ACTELION23.81%29 840
GENMAB14.75%12 865